A new study from Memorial Sloan Kettering Cancer Center highlights the promise of ulixertinib, a targeted therapy drug that blocks ERK, for treating certain forms of histiocytosis, including Erdheim-Chester Disease (ECD).
Led by Dr. Eli Diamond, a member of the ECDGA Medical Advisory Board, this research marks an exciting step forward in the treatment of MAPK-driven histiocytic disorders. For many in our community, like Joey, a member of the ECDGA whose journey continues to inspire us, these scientific breakthroughs represent far more than clinical progress. They offer hope.
Read the news article from MSKCC:
https://www.mskcc.org/news/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood
Access the full technical article in Cancer Cell:
https://www.sciencedirect.com/science/article/pii/S1535610825004064
At ECDGA, we are proud to support and share research that drives us closer to better care, more answers, and, someday, a cure.
The Erdheim-Chester Disease Global Alliance (ECDGA) does not provide medical advice, diagnoses, or treatments. All content is for informational purposes only. Please consult with a healthcare provider for medical concerns.